First Trust Advisors’s Coherus Oncology CHRS Stock Holding History

First Trust Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-27,297	Closed	-$102K	–	2353
2023 Q3	$102K	Buy	+27,297	New	+$126K	﹤0.01%	2326
2021 Q3	–	Sell	-39,093	Closed	-$541K	–	2534
2021 Q2	$541K	Sell	39,093 -52,678	-57%	-$746K	﹤0.01%	2258
2021 Q1	$1.34M	Buy	91,771 +15,601	+20%	+$265K	﹤0.01%	1885
2020 Q4	$1.32M	Sell	76,170 -12,812	-14%	-$228K	﹤0.01%	1778
2020 Q3	$1.63M	Buy	+88,982	New	+$1.66M	﹤0.01%	1476
2020 Q1	–	Sell	-48,741	Closed	-$878K	–	2365
2019 Q4	$878K	Sell	48,741 -121,006	-71%	-$2.23M	﹤0.01%	1931
2019 Q3	$3.44M	Buy	169,747 +140,107	+473%	+$2.8M	0.01%	1239
2019 Q2	$655K	Buy	+29,640	New	+$515K	﹤0.01%	2019
2019 Q1	–	Sell	-90,645	Closed	-$820K	–	2413
2018 Q4	$820K	Buy	+90,645	New	+$1.05M	﹤0.01%	1930
2017 Q2	–	Sell	-58,010	Closed	-$1.23M	–	2380
2017 Q1	$1.23M	Sell	58,010 -2,053	-3%	-$50.5K	﹤0.01%	1776
2016 Q4	$1.69M	Buy	+60,063	New	+$1.68M	0.01%	1549

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors's CHRS Position: Q4 2023 in Review

First Trust Advisors sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 27,297 shares — an estimated $102K sold.

First Trust Advisors first reported a position in CHRS in Q4 2016 and held it in 11 quarters. The position peaked at $3.44M in Q3 2019. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

First Trust Advisors reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
First Trust Advisors sold 27,297 Coherus Oncology shares in Q4 2023, an estimated $102K.
First Trust Advisors first reported a position in Coherus Oncology in Q4 2016 and held it in 11 quarters.
First Trust Advisors's Coherus Oncology position peaked at $3.44M in Q3 2019.
156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on First Trust Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.